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Abstract  
For prostate cancer patients, the Gleason score is ​one of the most important​ prognostic factors, 
potentially determining treatment independent of the stage. However, Gleason scoring is based 
on subjective microscopic examination of tumor morphology and suffers from poor 
reproducibility. Here we present a deep learning system (DLS) for Gleason scoring whole-slide 
images of prostatectomies. Our system was developed using 112 million pathologist-annotated 
image patches from 1,226 slides, and evaluated on an independent validation dataset of 331 
slides, where the reference standard was established by genitourinary specialist pathologists. 
On the validation dataset, the mean accuracy among 29 general pathologists was 0.61. The 
DLS achieved a significantly higher diagnostic accuracy of 0.70 (p=0.002) and trended towards 
better patient risk stratification in correlations to clinical follow-up data. Our approach could 
improve the accuracy of Gleason scoring and subsequent therapy decisions, particularly where 
specialist expertise is unavailable. The DLS also goes beyond the current Gleason system to 
more finely characterize and quantitate tumor morphology, providing opportunities for 
refinement of the Gleason system itself.  
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Introduction 
Adenocarcinoma of the prostate is the second most common cancer diagnosed in men, 
with approximately one in nine men diagnosed in their lifetime.​1​ For prostate cancer patients, 
subjective microscopic tissue examination remains the gold standard for diagnosis. Here, the 
Gleason score and tumor stage have remained the most powerful predictors of prognosis in 
virtually every large prostate cancer outcome study.​2​ The Gleason system was initially 
developed in 1966 and stratifies prostate malignancies by tumor architectural patterns.​ ​The 
system has since been revised significantly​3​,​4​ in an attempt to better reflect tumor biology. 
Importantly, the Gleason score (and its associated Gleason grade group​2​) is central to risk 
stratification and the National Comprehensive Cancer Network guidelines​5​, which are 
widely-used clinically to guide standardized patient management decisions. Despite its 
indisputable role in prognostication and patient management, Gleason scoring by pathologists is 
a subjective exercise and suffers from suboptimal interobserver and intraobserver variability, 
with reported Gleason score discordance ranging from 30-53%.​6–14  
A potential approach to increasing the consistency and accuracy of Gleason grading lies 
in the field of artificial intelligence, where recent advances have been applied productively to 
imaging diagnostic tasks across dermatology​15,16​, ophthalmology​17–20​, radiology​21–23​, and 
histopathology.​24–29​ Artificial intelligence systems have been developed for prostate cancer 
detection in needle core biopsies​26​ and Gleason grading of tissue microarrays​27​, which comprise 
carefully selected sub-regions of tumor specimens used for research purposes, outside of 
routine clinical workflow. These studies have not explored the task of Gleason grading 
specimens used for clinical diagnosis. 
Expertise and consistency in Gleason scoring have been shown to significantly improve 
its prognostic utility.​9,30​ We thus reasoned that the availability of an accurate Gleason scoring 
tool for the whole-slide sections used in clinical workflows could help address the problem of 
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grading variability, improve prognostication and optimize patient management.​ ​To this end, we 
developed a DLS to perform Gleason scoring and quantitation on prostatectomy specimens. 
The DLS accuracy is compared against a cohort of pathologists, where the reference standard 
was defined by genitourinary specialist pathologists. We further compared the risk stratification 
provided by our DLS, the cohort of pathologists, and our specialist-defined reference standard in 
predicting disease progression. Lastly, we also explored the potential of artificial intelligence to 
provide more fine-grained measures of tumor grading and the resulting potential to provide 
more precise prognostication.  
 
Results 
Overview of the Deep Learning System (DLS) and Data Acquisition. ​​Our approach is a 
2-stage DLS: first a deep convolutional neural network-based regional Gleason pattern (GP) 
classification followed by a k-nearest-neighbor-based whole-slide Gleason grade group 
classification (Fig. 1). The first stage was trained using image patches extracted from the slide 
and the corresponding label derived from pathologist-labeled pixel-level annotations (Fig. 1). In 
total, we collected and used 112 million image patches derived from 912 slides (approximately 
115,000 mm​2​ of tissue), which required approximately 900 pathologist hours to annotate. To our 
knowledge, this constitutes the largest pixel-annotated histopathology dataset, roughly 4x larger 
in annotated tissue area than the training slides in the widely used Camelyon16 dataset​24​. The 
second stage was trained using 1,159 slide-level classifications provided by pathologists. 
The DLS was evaluated on an independent validation dataset collected from three 
sources, consisting of 331 slides from 331 patients (Table 1). At least 3 pathologists provided 
initial reviews for each slide. A genitourinary specialist pathologist subsequently reviewed each 
slide along with the initial pathologists’ comments to provide a final grade for use as the 
reference standard (Methods). 
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Comparison of DLS to pathologists on Whole-Slide Gleason Scoring. ​​Independent of 
establishing the reference standard, we collected additional pathologist reviews on the 
validation dataset to compare with the DLS’s performance. The mean accuracy among the 29 
pathologists in classifying each slide’s grade group was 0.61 (95% confidence interval (CI): 
0.56-0.66). The DLS achieved an accuracy of 0.70 (95%CI 0.65-0.75), higher than the cohort of 
29 (p=0.002, Fig. 2a). A subgroup of 10 pathologists in this cohort reviewed the entire validation 
dataset, with individual accuracies ranged from 0.53 to 0.73 (mean: 0.64). The DLS was more 
accurate than 8 of these 10 pathologists (Fig. 2b, Supplementary Table 4). The remaining 19 
pathologists reviewed overlapping subsets of the validation set (see Methods), achieving 
individual accuracies ranging from 0.31 to 0.74 (mean: 0.60). Additional analyses are presented 
in Supplementary Tables 5-6 and Supplementary Fig. 1. 
We additionally looked at three grade group (GG) decision thresholds: GG≥2, GG≥3, 
and GG≥4. The DLS achieved areas under receiver operating characteristic curves (AUCs) of 
0.95-0.96 at each of these thresholds (Fig. 2c). The largest difference occurred at the GG≥4 
threshold, where the DLS demonstrated both a higher sensitivity and specificity than 9 out of 10 
individual pathologists. 
 
Comparison of DLS to pathologists on Gleason Pattern Quantitation. ​​In addition to the 
grade group, more granular reporting of the relative amounts of Gleason patterns is 
recommended by the International Society of Urological Pathology (ISUP), College of American 
Pathologists (CAP), World Health Organization (WHO), and recent publications.​31–34​ As such, we 
also compared the DLS’s accuracy in Gleason pattern quantitation to that of pathologists. 
Relative to the genitourinary pathologist reference standard, the DLS had a 4-6% lower mean 
absolute error than the average pathologist for quantitation of patterns 3 and 4 (Fig. 3). In 
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subgroup analysis, for slides in grade groups 2 and 3 (where the amount of pattern 4 can 
change the overall grade group), the DLS again achieved better quantitation (8% lower mean 
absolute error). The trend for grade groups 4 and 5 (where quantitation of pattern 5 is 
significant) was similar. More details are available in Supplementary Tables 7-8. 
 
Insights from DLS Region-Level Classifications. ​​Furthermore, we evaluated the DLS’s ability 
to classify tissue regions within each slide. We collected exhaustive region-level annotations for 
79 slides, performed by 3 pathologists per slide, and compared the predictions of the DLS to 
these annotations (see Fig. 4a for an example). We first characterized the DLS’s predictions by 
examining regions where the pathologists were concordant. For regions where all 3 pathologists 
agree on the same region classification (one of: non-tumor, Gleason pattern 3, 4, or 5), the DLS 
concurs 97% of the time. For the subset of these regions classified as a Gleason pattern, the 
DLS favors the same Gleason pattern as the pathologists 88% of the time (see Supplementary 
Results for an analysis of DLS errors).  
Next, we characterized the DLS’s prediction for regions where the pathologists were 
discordant by plotting the confidence score of the DLS for each category as a function of 
inter-pathologist agreement (Fig. 4b and Supplementary Fig. 2). ​For tissue regions where 
pathologists are concordant on Gleason pattern 3, discordant between 3 and 4, or concordant 
on Gleason pattern 4, the DLS’ prediction scores ​change smoothly with the pathologists’ 
classification distribution.​ The same trend is seen as we move from Gleason pattern 4 to 5. We 
further used the DLS’s prediction scores directly to classify regions as ​fine-grained Gleason 
patterns ​(e.g. Gleason patterns 3.3 or 3.7). We found that by doing so, that DLS was able to 
represent a more gradual transition from well-to-poor differentiation than allowed by the 
canonical coarse Gleason pattern buckets (Fig. 4c and Supplementary Fig. 3).  
6 
 
 
 
 
 
 
 
Measuring Effectiveness of Gleason Scoring in Risk Stratification for Disease 
Progression. ​​Lastly, we compared the ability of the DLS, the cohort of pathologists, and 
genitourinary specialist pathologists (who comprised the reference standard) to risk stratify 
patients for biochemical recurrence or disease progression (see Methods). In this analysis, we 
measured prognostic performance using the ​c-index​, which is an extension of​ AUC that​ handles 
censored data in survival analysis. On the validation set, the DLS-predicted Gleason grade 
group achieved a c-index of 0.65. The pathologist-provided grade groups yielded a median 
c-index of 0.63 (see Methods), while the genitourinary specialist pathologists achieved a c-index 
of 0.69. Kaplan-Meier and hazard ratio analyses using a binary GG≥3 threshold, where hazard 
ratios for GG3 have previously been shown to be three-fold higher than GG2​2​, to stratify 
patients into ‘high risk’ and ‘low risk’ categorizations showed the same trend (Fig. 5).  
In addition to the risk stratification performance of GGs, we also used Cox models​35​ to 
evaluate the prognostic ability of the underlying quantified Gleason patterns. The c-indices of 
these models were 0.697​ for the DLS, ​0.674​ for the cohort of 29 pathologists​, and 0.690 for the 
specialist-defined reference standard. As proof of concept that finer grained Gleason patterns 
can improve risk stratification, we also evaluated Cox-regression models trained on a more 
granular representation of the tumor pattern composition. Adding ‘GP3.5’ to the canonical 
Gleason patterns (thus summarizing the tumor composition as %GP3, %GP3.5, %GP4, and 
%GP5) raised the c-index to 0.704​. F​urther adding %GP4.5 resulted in a c-index of 0.702 
(Supplementary Table 10). 
 
Discussion 
The present study shows that a DLS was more accurate than a cohort of 29 
board-certified pathologists in Gleason scoring whole-slide images from prostatectomy patients. 
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The pathologists in this study had a 66% Gleason score concordance (61% Gleason grade 
group concordance) with genitourinary specialist pathologists, which is at the high end of 
several reported inter-pathologist Gleason score concordances of 47%-70%​6–14​. 
Previous studies have highlighted the value of expertise in pathologic interpretation. 
Central histologic reviews provided by pathologists experienced in genitourinary pathology 
improved prognostication relative to reviews provided by the local institution. Encouragingly, the 
risk stratification performance (as measured by the c-index and hazard ratio) in this study 
followed the same trend.​9,30​ Due to the importance of genitourinary expertise in pathologic 
review, a second review has been recommended for high-risk patients after prostatectomy and 
for needle biopsies prior to prostatectomy.​8,9,36​ In routine pathologic workflows, DLS-predicted 
Gleason scores could be computed on-demand and serve as a decision support tool. Future 
research is necessary to evaluate the potential clinical impact of the use of these predicted 
Gleason scores for patient prognostication and associated therapy decisions. 
 
Implications of DLS region-level pattern classifications and quantitation. ​​We further 
explored the implications of the DLS on each step of Gleason scoring and their respective 
scoring variability. The first aspect of Gleason scoring is the region-level classification of 
Gleason patterns across each slide. In this step, two-dimensional histologic examination of the 
three-dimensional tissue structures creates inherent ambiguity. Substantial additional variability 
arises from applying discrete categorizations to glandular differentiation that lies on a 
continuous spectrum, such as the Gleason pattern 3/4 transition between small glands and 
poorly defined acinar structures or the Gleason pattern 4/5 transition between fused glands and 
nests or cords.​12,37,38​ Our data show that for regions where pathologists are discordant in 
Gleason pattern categorization, where the underlying histology is likely closer to the cusp 
between patterns, the DLS reflects this ambiguity in its prediction scores (Fig. 4b) and 
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demonstrates the potential to assign finer-grained Gleason patterns (Fig. 4c). This finer-grained 
categorization provides opportunities to mitigate variability stemming from coarse categorization 
of a continuum, and opens avenues of research for more precise risk stratification (see 
Supplementary Table 10). 
The next step in Gleason scoring after region-level categorization involves visual 
quantitation of the relative amounts of each Gleason pattern to determine the most prevalent 
patterns. Quantitation also allows for more granular prognostication. For example, prior studies 
have shown that prognosis of grade group 2-3 patients worsened for increases of percent 
Gleason pattern 4 as small as 5-10%.​34​ As such, reporting of the quantitation of Gleason 
patterns is recommended.​4,31,39​ However, visual quantitation is associated with inherent 
subjectivity.​40​ In this regard, the DLS bypasses the variability introduced by visual quantitation 
through direct quantitation of Gleason patterns from its underlying region categorizations. The 
DLS’s natural advantage in this regard and its more accurate quantitation than the cohort of 
pathologists (as measured by agreement with a specialist-adjudicated reference standard) 
suggest opportunity for more precise prognostication. 
 
Relation to previous works. ​​The above results complement previous works on the application 
of deep learning to prostate cancer histopathology. Campanella et al. demonstrated the use of 
deep learning in needle core biopsies to facilitate the detection of cancer foci.​26​ Arvaniti et al. 
applied deep learning to Gleason score tissue microarrays.​27​ This study complements prior work 
by applying deep learning to Gleason grading specimens that are more representative of a 
diversity of histologies and artifacts seen in routine clinical practice, and by directly comparing 
algorithmic performance with pathologists on a large multi-institutional dataset, with a rigorous 
reference standard defined by a team of board-certified pathologists and genitourinary specialist 
pathologists.  
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Another notable aspect of our work is the complexity and scale of the annotations 
required to develop our DLS. The complexity of Gleason grading has been discussed above; 
formalizing these interpretations as concrete annotations for training the DLS involved 
significant complexity, for example, “mixed” Gleason grades, artifacts, non-prostate tissue such 
as seminal vesicles, pre-malignant tissue, and uncommon variants. Please see Methods and 
Supplementary Methods for our detailed protocol. The size of this dataset was a key contributor 
to the accuracy of our DLS; training different models on titrated fractions of our dataset suggests 
that the DLS performance benefited greatly from the size of the dataset, and may yet improve 
with more or better quality data. Given the interobserver variability in Gleason grading, we also 
increased the accuracy of the pixel-level annotations in our tuning set by collecting triplicate 
annotations for each slide (see Methods and Supplementary Methods for details about the 
annotation and DLS training protocol). 
In addition, our DLS stage-1 development process includes large scale, continuous 
“hard-negative mining” which aims to improve algorithm performance by running inference on 
the entire training dataset to isolate the hardest examples and further refine the algorithm using 
these examples. For histopathology applications on whole-slide imaging, this is a 
computationally expensive process, requiring inference over 112 million image patches in our 
training dataset. While previous works employing deep learning on histopathology images have 
employed hard negative mining in an offline “batch-mode”​24,41,42​, we observed that performance 
improves with the frequency of inference on the entire training dataset, resulting in the 
“quasi-online” hard-negative mining approach (>30,000 DLS stage-1 inferences per second) 
used here. We anticipate that the benefits of this continuous hard negative mining approach 
may also be applicable to developing other histopathology deep learning algorithms. 
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Limitations and future work. ​​This study has important limitations that would need to be 
addressed prior to implementation of associated tools in clinical practice. Unlike clinical 
environments, which are still largely based on glass slide review, this study focuses on digital 
review. Further, clinical environments enable pathologists to review additional sections, stains, 
or order consults for challenging cases. To account for this, pathologists were asked to indicate 
when they would prefer additional resources or consults to provide a more confident diagnosis. 
Corresponding sensitivity analysis excluding these cases is provided in Supplementary Table 9, 
showing qualitatively similar results.  
Next, this study focuses on grading acinar prostatic adenocarcinoma (the vast majority of 
prostate cancer cases) in prostatectomy specimens, where the grade group informs 
postoperative treatment decisions rather than the decision to undergo the prostatectomy itself. 
As such, clinical outcomes after prostatectomy are less confounded by divergent treatment 
pathways than biopsies, supporting analyses of correlations with clinical follow-up data. In 
addition, prostatectomy specimens contain more tissue than biopsies, providing greater context 
during histological examination and improving the quality of the reference standard. However, 
important future work will generalize and validate the DLS for biopsies, other histologic variants, 
and other prognostic categorizations to aid clinical decisions throughout prostate cancer 
treatment pathways. Lastly, validation on larger clinically annotated datasets is required to 
evaluate the statistical significance of trends associated with prognostication demonstrated in 
this work.  
 
Conclusions 
We have developed a DLS that outperforms a cohort of 29 generalist pathologists in 
Gleason scoring prostatectomy whole-slide images. Additionally, the DLS provides more 
accurate quantitation of Gleason patterns, finer-grained discretization of the well-to-poor 
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differentiation spectrum, and opportunities for better risk stratification. In doing so, our DLS 
demonstrates the potential to enhance the clinical utility of the Gleason system for better 
treatment decisions for patients with prostatic adenocarcinoma. 
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Methods 
 
Acquisition of Data.​​ De-identified, digitized whole-slide images of hematoxylin-and-eosin- 
(H&E-) stained formalin-fixed paraffin-embedded (FFPE) prostatectomy specimens were 
obtained from 3 sources: a public repository (The Cancer Genome Atlas, TCGA​43​, n=397 
patients), a large tertiary teaching hospital in the U.S. (n=361 patients), and an independent 
medical laboratory (n=11 patients, Table 1, Supplementary Table 1). This work was approved 
by the hospital’s Institutional Review Board. 
From TCGA we included all FFPE prostatectomy cases, the slides for which were 
scanned using a mix of scanners, including both Aperio and Hamamatsu scanners, and a mix of 
resolutions: ≈0.25µm/pixel (“40X magnification”) and ≈0.5µm/pixel (“20X magnification”). From 
the hospital we included all prostatectomy cases where FFPE tissue blocks or slides were 
available based on a review of de-identified pathology notes. From the independent laboratory 
we obtained additional cases based on pathology reports to improve the representation of 
Gleason grade groups 4-5 in our study cohort (Table 1). From these sources, slides were 
obtained for cases within the 10-year Clinical Laboratory Improvement Amendments (CLIA) 
archival requirement, and tissue blocks for deaccessioned cases. Blocks were cut to produce 
sections of five-micron thickness and stained by CLIA-certified commercial laboratories (San 
Diego Pathology, San Diego, CA and Marin Medical Laboratories, Greenbrae, CA). Slides were 
digitized using a Leica Aperio AT2 scanner at a resolution of 0.25 µm/pixel. 
Cases were randomly assigned to either the development (training/tuning) or 
independent validation datasets. For the 380 cases assigned to the validation dataset, 
pathologists identified one representative tumor-containing slide per case (see Grading section). 
Among these slides, 27 were excluded due to the presence of prostate cancer variants 
(Supplementary Table 2), 2 due to extensive artifacts or poor staining that hindered diagnosis, 
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and 20 because of the inability of a genitourinary pathology specialist to confidently assign a 
diagnosis (Supplementary Table 3). The final validation dataset consisted of the remaining 331 
slides (n=183 from TCGA, n=144 from the hospital, and n=4 from the laboratory). 
 
Overview of Pathologists’ Annotations and Reviews. ​​A total of 35 pathologists reviewed 
slides for this study, all of whom completed residency in human anatomical pathology. 
Twenty-nine pathologists were U.S.-board-certified (the “cohort of 29”), and another 3 had 
genitourinary specialization (1 Canadian-board-certified and 2 U.S.-board-certified). The 
remaining 3 pathologists were formerly board-certified or certified outside of North America, and 
provided annotations for the training and tuning datasets but not the validation dataset. 
We collected slide-level reviews and region-level annotations from pathologists. 
Slide-level reviews categorize each slide into its Gleason grade group. Region-level annotations 
label specific tissue regions (such as specific Gleason patterns) within a slide. We describe the 
annotation protocol for the validation dataset here, and include additional details and the 
protocol for the training and tuning datasets in the “Grading” section and Supplementary Figure 
5 in the Supplement. 
 
Collection of Slide-Level Reference Standard. ​​The slide-level reference standard was used 
to validate the DLS’s and general pathologists’ performance.  For each slide, the reference 
standard was provided by one genitourinary specialist pathologist. To improve accuracy, the 
specialist reviewing each slide also had access to initial Gleason pattern percentage estimates 
and free-text comments from prior reviews of at least 3 general pathologists. The specialist then 
determined the final GP percentages for tumor of each Gleason Pattern (GP): %GP3, %GP4, 
and %GP5 for use as the reference standard. We derived the slide-level Gleason score and 
corresponding grade group (1, 2, 3, or 4-5) based on the predominant and next-most-common 
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Gleason patterns provided by the genitourinary specialist, avoiding variability introduced by 
inconsistent application of “tertiary replacement” (see “Grading” in the Supplement). All slides 
were reviewed in a manner consistent with ISUP 2014 and CAP guidelines with no time 
constraint.​4,31 
 
Collection of Slide-Level Reviews for Pathologists’ Performance. ​​To evaluate general 
pathologists’ performance at Gleason scoring, we collected additional slide-level reviews for 
each slide, independent from those collected for determining the reference standard. These 
reviews came from a total of 29 pathologists. From this cohort, 10 pathologists provided reviews 
for every slide in the validation dataset. The remaining 19 pathologists reviewed overlapping 
subsets of the validation set (median: 53 slides, range: 41-64), collectively providing three 
reviews per slide.  
 
Collection of Region-Level Annotations. ​​To compare region-level DLS predictions to 
pathologist interpretations, pathologists provided annotations of specific tissue regions within a 
slide, outlining individual glands or regions and providing an associated label (non-tumor, or GP 
3, 4, or 5). For these time-consuming region-level annotations, a subset of the validation dataset 
(79 of 331 slides) were selected based on slide-level grade group diversity. Each of these 79 
slides was exhaustively annotated by three pathologists (​>​95% tissue coverage; taking on 
average 3 hours per pathologist per slide). Only regions for which all three pathologists provided 
a label were used for validation. 
 
Clinical Follow-up Data.​​ To measure risk stratification performance, we used additional clinical 
follow-up data. For the TCGA subset of data, we used the progression free interval as the 
clinical endpoint, as recommended by the authors of the TCGA Clinical Data Resource.​44​ For 
15 
 
 
 
 
 
 
the hospital subset, biochemical recurrence, as defined by a postoperative prostate specific 
antigen (PSA) measurement of ​>​ 0.4​45​, was used as the clinical endpoint. Clinical endpoints 
were not available from the medical laboratory and for a small number of cases from TCGA and 
the hospital. Of the 331 validation slides, 320 had available clinical follow-up data. 
 
Deep Learning System (DLS).​​The DLS consists of 2 stages (Fig. 1), which correspond to the 
region-level annotations and slide-level reviews: first a regional classification, and subsequent 
whole-slide Gleason grade group classification. The first stage segments each slide into small 
image patches and feeds each patch into a convolutional neural network that classifies each 
patch as one of four classes: non-tumor, or Gleason pattern 3, 4, or 5. When applied to the 
entire whole-slide image, this stage outputs a “heatmap” indicating the categorization of each 
patch in the tissue section. The second stage consists of a nearest-neighbor classifier that uses 
a summary of the heatmap output from the first stage to categorize the grade group of each 
slide. We briefly outline the DLS development procedure below, and provide additional details in 
the “Deep Learning System” section in the Supplement. 
The first stage’s convolutional neural network is a modified InceptionV3​46​, that classifies 
each tissue region of roughly 32✕32µm by using input image patches of 911✕911µm centered 
on the region. The label for each region was derived from the pathologist-provided region-level 
annotations (see Supplementary Methods, “Grading” section). Ensembling and hard-negative 
mining were employed to further improve model performance (see Supplementary Methods, 
“Hard-negative Mining” section). 
In the second stage of the DLS, we first obtained a categorical prediction for each region 
by taking the class with the highest calibrated likelihood, where calibration weights were 
determined empirically using the tuning set. Next, for each slide, the number of regions 
predicted as each category was summarized and used for evaluation of (GP) quantitation 
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(%GP3, %GP4, and %GP5). The three %GPs, together with the tumor involvement, were used 
as features (Fig. 1), similar to what a pathologist would need for Gleason scoring. Finally, we 
trained k-nearest neighbor classifiers for several prediction tasks: four-class grade group (GG) 
classification (1, 2, 3 or 4-5), and each of three binary classifications of GG​>​2, GG​>​3, and 
GG​>​4. 
 
Statistical Analysis. ​​We assessed the DLS’s Gleason scoring performance relative to the 
reference standard for slide-level and region-level classifications. For slide-level grade group 
categorization, we compared the accuracy of the DLS to the mean of the 29 individual 
pathologist accuracies, where accuracy is the fraction of exact matches with the reference 
standard. This provided equal representation of each pathologist despite their differing number 
of reviews. We additionally measured performance using accuracy adjusted by a 
population-level grade group distribution​47​, and Cohen’s kappa​48​. For the three binary 
classifications of slide-level grade group, we used the area under the receiver operating 
characteristic curve (AUC). For quantitation of relative Gleason patterns in the tumors, we 
computed the mean absolute error (MAE). 
For clinical follow-up analysis, the concordance index was used to measure the overall 
effectiveness of grade group risk-stratification with respect to an adverse clinical endpoint 
(disease progression or biochemical recurrence as described above). The hazard ratio and 
associated Kaplan-Meier curves were used to evaluate risk-stratification at the binary 
classification of GG ​>​ 3. For these risk stratification analyses, the cohort-of-29 pathologists 
Grade Group classifications were sampled to approximate equal representation of each 
pathologist (see “Statistical Analysis” in the Supplement). Analysis on the sampled 
classifications that produced the median concordance and hazard ratios respectively among 
999 sampling iterations is reported here. 
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Confidence intervals for all evaluation metrics were computed using a bootstrap 
approach (see “Statistical Analysis” in the Supplement). All statistical tests were 2-sided 
permutation tests. A p-value<0.05 was considered statistically significant. No adjustment for 
multiple comparisons was made. These analyses were performed in Python (v2.7.6), using the 
scikit-learn (v0.19.1) and lifelines (v0.12.0) libraries. 
 
Reporting Summary. ​​Further information on experimental design is available in the Nature 
Research Reporting Summary linked to this article. 
 
Code availability. 
Code Availability. The deep learning framework used here (TensorFlow) is available at 
https://www.tensorflow.org/​. The Python libraries used for computation and plotting of the 
performance metrics (SciPy, NumPy, Lifelines, and MatPlotLib) are available under 
https://www.scipy.org/​, ​http://www.numpy.org/​, https://github.com/CamDavidsonPilon/lifelines/, 
and ​https://matplotlib.org/​, respectively. 
 
Data availability. 
The dataset from TCGA that was used in this study is available from the Genomic Data 
Commons portal (https://portal.gdc.cancer.gov/), which is based upon data generated by the 
TCGA Research Network (http://cancergenome.nih.gov/). The other datasets are not publicly 
available due to restrictions in the data sharing agreements with the data sources. The use of 
de-identified tissue for this study was approved by an Institutional Review Board (IRB). 
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Figures/Tables 
 
 
Fig. 1 | Illustration of the development and usage of the two-stage deep learning system 
(DLS). ​​Developing the DLS involves training two machine learning models. Stage 1 is an 
ensembled deep convolutional neural network (CNN) that classifies every region in the slide as 
non-tumor, or its Gleason pattern (GP). Training the stage 1 CNN involves first collecting 
pathologists’ annotations (Annotation Masks) of whole-slide images at the region level, and then 
generating “sampling masks” indicating the locations of each of the four classes (non-tumor, 
GP3, GP4, and GP5) for each slide. Over the course of millions of training iterations, sampled 
image patches and associated labels are used to train the constituent CNNs in the ensembled 
stage 1 CNN model. During the training process, we performed hard-negative mining by 
periodically applying each individual partially trained model to the entire training corpus of 
whole-slide images. Comparison of these intermediate inference results to the original 
annotations highlights the most difficult image patches, and we focus training on these patches. 
Stage 2 involves first collecting pathologists’ labels of the Gleason grade group (GG) for each 
slide. Next, the predictions of the stage 1 model are calibrated and converted to 4 features that 
indicate the amount of tumor and each GP in the slide. k-nearest neighbor (kNN) classifiers are 
then trained to predict the GG (1, 2, 3, or 4-5), or whether the GG is above specific thresholds 
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(GG​>​2, GG​>​3, or GG​>​4). For more details, please refer to the “Deep Learning System” section 
in the Supplement.   
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Fig. 2 | Comparison of prostate cancer Gleason scoring performance of the deep learning 
system (DLS) with pathologists. a, ​​Accuracy of the DLS (in red) compared with the mean 
accuracy among a cohort-of-29 pathologists (in green). Error bars indicate 95% confidence 
intervals. ​b, ​​Accuracy of the DLS compared to 10 individual pathologists (among the cohort of 
29, indicated by pathologists A-J) who reviewed all of the slides in the validation set. See eTable 
4 in the Supplement for more details. ​c, ​​The receiver operating characteristic curves compare 
the sensitivity and specificity of the DLS with individual pathologists and the cohort-of-29 
pathologists for binary classification of whether the Gleason grade group (GG) is above the 
thresholds of GG≥2, GG≥3 and GG≥4. AUCs and associated 95% confidence intervals for the 
DLS are provided in the legend. Higher and to the left indicates better performance. 
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Fig. 3 | Comparison of the deep learning system (DLS) with pathologists for Gleason 
Pattern (GP) quantitation.​​ Each dot indicates the mean average error (lower is better) for 
Gleason pattern quantitation, with error bars show the 95% confidence intervals. Left: overall 
Gleason pattern quantification results among all slides. Right: subgroup analysis where Gleason 
pattern quantification is of particular importance: grade group 2-3 slides where percent of 
Gleason pattern 4 can change the overall grade group, and grade group 4-5 slides where 
percent of Gleason pattern 5 reporting is recommended by the College of American 
Pathologists.  
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Fig. 4 | Assessing the region-level classification of the DLS. a, ​​3 pathologists annotated this 
slide with general concordance on the localization of tumor areas, but poor agreement on the 
associated Gleason patterns: a ‘pure’ grade like Gleason pattern 3, 4, or 5, or a mixed grade 
comprising features of more than one pure pattern. The DLS assigned each image patch to a 
fine-grained Gleason pattern, as illustrated by the colors interpolating between Gleason patterns 
3 (green), 4 (yellow), and 5 (red). See the “Fine-grained Gleason Pattern” section in the 
Supplement. ​b,​​ Quantification of the observations from panel A across ​79 slides (41 million 
annotated image patches)​ for which 3 pathologists exhaustively categorized every slide. The 
violin plots indicate DLS prediction-likelihood distributions. The white dots and black bars 
identify medians and interquartile ranges, respectively. The predicted likelihood of each Gleason 
pattern by the DLS changes smoothly with the pathologists’ classification distribution. See 
Supplementary Fig. 2 for a similar analysis on images with mixed-grade labels. ​c, ​​The 
continuum of Gleason patterns learned by the DLS reveals finer categorization of the 
well-to-poorly differentiated spectrum (see “Fine-grained Gleason Pattern” section in the 
Supplement). Each displayed image region is the region closest (of millions in our validation 
dataset) to its labeled quantitative Gleason pattern. Columns 1, 4, and 7 represent regions for 
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which the highest confidence predictions are Gleason patterns 3, 4, and 5 respectively. The 
columns in between represent quantitative Gleason patterns between these defined categories. 
See Supplementary Fig. 3 for additional examples.  
24 
 
 
 
 
 
 
 
Fig. 5 | Comparison of risk stratification between pathologists, deep learning system, and 
the specialist-defined reference standard. a, ​​Concordance index provided by each entity’s 
grade group (GG) classification (GGs 1, 2, 3, 4-5) in stratisfying adverse clinical endpoints of 
disease progression or biochemical recurrence (BCR) (see “Clinical Follow-up Data” in 
Methods). 95% confidence intervals were obtained by bootstrapping. For the cohort-of-29 
pathologists, the median c-index is reported (See “Statistical Analysis” in Supplementary 
Methods). ​b,​​ Kaplan-Meier curves using a binary threshold (GG​>​3) for risk stratification. Dotted 
lines correspond to the lower risk group (GG1-2) and solid lines correspond to the higher risk 
group (GG3-5). A larger separation between the risk groups indicates better risk stratification. 
Tick marks indicate censorship events. For the cohort-of-29 pathologists, analyses of sampled 
Grade group classifications that produced a median hazard ratio are plotted here (See 
“Statistical Analysis” in Supplementary Methods).  
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 Source or Diagnosis TCGA 
Tertiary 
Teaching 
Hospital 
Medical 
Laboratory Total 
Number of 
Patients 
Patients with available 
prostatectomy specimens 219 157 4 380 
Excluded due to 
non-gradable prostate 
cancer variants 
22 5 0 27 
Excluded due to extensive 
image artifacts or poor 
staining 
2 0 0 2 
Specialist unable to provide 
confident diagnosis 12 8 0 20 
 
Slide-level 
Gleason grade 
group 
Patients in study (1 slide 
per patient) 183 144 4 331 (100%) 
Grade group 1 10 67 0 77 (23%) 
Grade group 2 77 57 0 134 (40%) 
Grade group 3 46 14 2 62 (19%) 
Grade group 4-5 50 6 2 58 (18%) 
     Grade group 4 10 2 0 12 (4%) 
     Grade group 5 40 4 2 46 (14%) 
Region-level 
Gleason 
pattern 
annotations 
Number of slides 62 14 3 79 
Non-tumor (patches) 18,022,643 10,879,735 2,152,853 31,055,231 
Gleason pattern 3 (patches) 2,445,437 343,685 2,016 2,791,138 
Gleason pattern 4 (patches) 4,288,977 8,280 106,227 4,403,484 
Gleason pattern 5 (patches) 1,797,331 326 129,059 1,926,716 
Table 1: Number and breakdown of slides in the validation dataset. ​​The validation set 
contains prostatectomy cases from three sources. A representative slide was selected from 
each patient’s case. The reference standard for the Gleason scores in the validation set was 
established by an initial review by at least 3 pathologists from a cohort of 19 and then 
26 
 
 
 
 
 
 
adjudication by 1 of 3 genitourinary specialists. The low prevalence of grade groups 4 and 5 in 
our dataset prompted us to merge these two groups for more reliable statistical comparisons. 
  
27 
 
 
 
 
 
 
Acknowledgements 
For technical advice and discussion, we thank the following, who are all employees of Alphabet 
Inc: Tim Hesterberg, PhD, Michael Howell, MD, MPH, David Miller, MS, Alvin Rajkomar, MD. 
For software infrastructure, logistical support, and slide digitization services, we thank members 
of the Google AI Healthcare Pathology team. Lastly, we are deeply grateful to the pathologists 
who provided annotations for this study. 
 
Author Contributions 
K.N., D.F., Y.L., F.T., J.D.H., M.C.S. designed the experiments; K.N., D.F., Y.L., C.C., E.W., 
J.W. wrote code to achieve different tasks; F.T., N.O., J.S., A.M., J.W., L.P., R.M., G.S.C., 
C.H.M. acquired the tissue samples for use in the study and provided strategic support; M.B.A., 
A.J.E., A.R.S. provided labels for use in measuring algorithm performance; M.S.C. supervised 
the project; K.N., D.F., Y.L., C.C., J.D.H. wrote the manuscript with the assistance and feedback 
of all other co-authors.  
 
Competing interests 
K.N., D.F., Y.L., C.C., E.W., F.T., G.S.C., R.M., L.P., C.H.M., J.D.H., and M.S.C. are employees 
of Google Inc. and own Alphabet stock. 
 
Disclaimer 
The views expressed in this article are those of the author(s) and do not necessarily reflect the 
official policy or position of the Department of the Navy, Department of Defense, nor the U.S. 
Government. A.M., N.O., J.L.S., and J.H.W. are military Service members. This work was 
prepared as part of their official duties. Title 17, U.S.C., §105 provides that copyright protection 
28 
 
 
 
 
 
 
under this title is not available for any work of the U.S. Government. Title 17, U.S.C., §101 
defines a U.S. Government work as a work prepared by a military Service member or employee 
of the U.S. Government as part of that person’s official duties. 
 
  
29 
 
 
 
 
 
 
References 
1. Prostate Cancer - Cancer Stat Facts. Available at: 
https://seer.cancer.gov/statfacts/html/prost.html.​ (Accessed: 22nd August 2018) 
2. Epstein, J. I. ​et al.​ A Contemporary Prostate Cancer Grading System: A Validated 
Alternative to the Gleason Score. ​Eur. Urol.​ ​69,​​ 428–435 (2016). 
3. Epstein, J. I., Allsbrook, W. C., Amin, M. B. & Egevad, L. L. The 2005 International Society 
of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic 
Carcinoma. ​Am. J. Surg. Pathol.​ ​29,​​ 1228–1242 (2005). 
4. Epstein, J. I. ​et al.​ The 2014 International Society of Urological Pathology (ISUP) 
Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading 
Patterns and Proposal for a New Grading System. ​Am. J. Surg. Pathol.​ ​40,​​ 244–252 
(2016). 
5. NCCN Clinical Practice Guidelines in Oncology. Available at: 
https://www.nccn.org/professionals/physician_gls/default.aspx#prostate.​ (Accessed: 14th 
August 2018) 
6. Persson, J. ​et al.​ Interobserver variability in the pathological assessment of radical 
prostatectomy specimens: findings of the Laparoscopic Prostatectomy Robot Open 
(LAPPRO) study. ​Scand. J. Urol.​ ​48,​​ 160–167 (2014). 
7. Veloso, S. G. ​et al.​ Interobserver agreement of Gleason score and modified Gleason score 
in needle biopsy and in surgical specimen of prostate cancer. ​Int. Braz J Urol​ ​33,​​ 639–46; 
discussion 647–51 (2007). 
8. Montironi, R., Lopez-Beltran, A., Cheng, L., Montorsi, F. & Scarpelli, M. Central prostate 
pathology review: should it be mandatory? ​Eur. Urol.​ ​64,​​ 199–201; discussion 202–3 
(2013). 
30 
 
 
 
 
 
 
9. Bottke, D. ​et al.​ Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate 
cancer: impact of pathology review on analysis. ​Eur. Urol.​ ​64,​​ 193–198 (2013). 
10. Egevad, L. ​et al.​ Standardization of Gleason grading among 337 European pathologists. 
Histopathology​ ​62,​​ 247–256 (2013). 
11. Netto, G. J., Eisenberger, M., Epstein, J. I. & TAX 3501 Trial Investigators. Interobserver 
variability in histologic evaluation of radical prostatectomy between central and local 
pathologists: findings of TAX 3501 multinational clinical trial. ​Urology​ ​77,​​ 1155–1160 
(2011). 
12. Allsbrook, W. C., Jr ​et al.​ Interobserver reproducibility of Gleason grading of prostatic 
carcinoma: urologic pathologists. ​Hum. Pathol.​ ​32,​​ 74–80 (2001). 
13. Allsbrook, W. C., Jr ​et al.​ Interobserver reproducibility of Gleason grading of prostatic 
carcinoma: general pathologist. ​Hum. Pathol.​ ​32,​​ 81–88 (2001). 
14. Mikami, Y. ​et al.​ Accuracy of gleason grading by practicing pathologists and the impact of 
education on improving agreement. ​Hum. Pathol.​ ​34,​​ 658–665 (2003). 
15. Esteva, A. ​et al.​ Dermatologist-level classification of skin cancer with deep neural networks. 
Nature​ ​542,​​ 115–118 (2017). 
16. Haenssle, H. A. ​et al.​ Man against machine: diagnostic performance of a deep learning 
convolutional neural network for dermoscopic melanoma recognition in comparison to 58 
dermatologists. ​Ann. Oncol.​ ​29,​​ 1836–1842 (2018). 
17. Gulshan, V. ​et al.​ Development and Validation of a Deep Learning Algorithm for Detection 
of Diabetic Retinopathy in Retinal Fundus Photographs. ​JAMA​ ​316,​​ 2402–2410 (2016). 
18. Ting, D. S. W. ​et al.​ Development and Validation of a Deep Learning System for Diabetic 
Retinopathy and Related Eye Diseases Using Retinal Images From Multiethnic Populations 
With Diabetes. ​JAMA​ ​318,​​ 2211–2223 (2017). 
19. Burlina, P. M. ​et al.​ Automated Grading of Age-Related Macular Degeneration From Color 
31 
 
 
 
 
 
 
Fundus Images Using Deep Convolutional Neural Networks. ​JAMA Ophthalmol.​ ​135, 
1170–1176 (2017). 
20. De Fauw, J. ​et al.​ Clinically applicable deep learning for diagnosis and referral in retinal 
disease. ​Nat. Med.​ ​24,​​ 1342–1350 (2018). 
21. Kermany, D. S. ​et al.​ Identifying Medical Diagnoses and Treatable Diseases by 
Image-Based Deep Learning. ​Cell​ ​172,​​ 1122–1131.e9 (2018). 
22. Rajpurkar, P. ​et al.​ CheXNet: Radiologist-Level Pneumonia Detection on Chest X-Rays with 
Deep Learning. ​arXiv [cs.CV]​ (2017). 
23. Chilamkurthy, S. ​et al.​ Deep learning algorithms for detection of critical findings in head CT 
scans: a retrospective study. ​Lancet​ (2018). doi:​10.1016/S0140-6736(18)31645-3 
24. Ehteshami Bejnordi, B. ​et al.​ Diagnostic Assessment of Deep Learning Algorithms for 
Detection of Lymph Node Metastases in Women With Breast Cancer. ​JAMA​ ​318, 
2199–2210 (2017). 
25. Liu, Y. ​et al.​ Detecting Cancer Metastases on Gigapixel Pathology Images. ​arXiv [cs.CV] 
(2017). 
26. Campanella, G., Silva, V. W. K. & Fuchs, T. J. Terabyte-scale Deep Multiple Instance 
Learning for Classification and Localization in Pathology. ​arXiv [cs.CV]​ (2018). 
27. Arvaniti, E. ​et al.​ Automated Gleason grading of prostate cancer tissue microarrays via 
deep learning. ​Sci. Rep.​ ​8,​​ 12054 (2018). 
28. Steiner, D. F. ​et al.​ Impact of Deep Learning Assistance on the Histopathologic Review of 
Lymph Nodes for Metastatic Breast Cancer. ​Am. J. Surg. Pathol.​ (2018). 
doi:​10.1097/PAS.0000000000001151 
29. Liu, Y. ​et al.​ Artificial Intelligence–Based Breast Cancer Nodal Metastasis Detection. ​Arch. 
Pathol. Lab. Med.​ (2018). doi:​10.5858/arpa.2018-0147-oa 
30. van der Kwast, T. H. ​et al.​ Impact of pathology review of stage and margin status of radical 
32 
 
 
 
 
 
 
prostatectomy specimens (EORTC trial 22911). ​Virchows Arch.​ ​449,​​ 428–434 (2006). 
31. Srigley, J. R. ​et al.​ Protocol for the examination of specimens from patients with carcinoma 
of the prostate gland. ​Arch. Pathol. Lab. Med.​ ​133,​​ 1568–1576 (2009). 
32. Humphrey, P. A., Moch, H., Cubilla, A. L., Ulbright, T. M. & Reuter, V. E. The 2016 WHO 
Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate 
and Bladder Tumours. ​Eur. Urol.​ ​70,​​ 106–119 (2016). 
33. Epstein, J. I., Amin, M. B., Reuter, V. E. & Humphrey, P. A. Contemporary Gleason Grading 
of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 
2014 International Society of Urological Pathology (ISUP) Consensus Conference on 
Gleason Grading of Prostatic Carcinoma. ​Am. J. Surg. Pathol.​ ​41,​​ e1–e7 (2017). 
34. Sauter, G. ​et al.​ Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and 
Prostatectomy Specimens. ​Eur. Urol.​ ​69,​​ 592–598 (2016). 
35. Cox, D. R. Regression Models and Life-Tables. in ​Springer Series in Statistics​ 527–541 
(1992). 
36. Brimo, F., Schultz, L. & Epstein, J. I. The value of mandatory second opinion pathology 
review of prostate needle biopsy interpretation before radical prostatectomy. ​J. Urol.​ ​184, 
126–130 (2010). 
37. Zhou, M. ​et al.​ Diagnosis of ‘Poorly Formed Glands’ Gleason Pattern 4 Prostatic 
Adenocarcinoma on Needle Biopsy: An Interobserver Reproducibility Study Among 
Urologic Pathologists With Recommendations. ​Am. J. Surg. Pathol.​ ​39,​​ 1331–1339 (2015). 
38. Shah, R. B. ​et al.​ Diagnosis of Gleason Pattern 5 Prostate Adenocarcinoma on Core 
Needle Biopsy. ​Am. J. Surg. Pathol.​ ​39,​​ 1242–1249 (2015). 
39. Gordetsky, J. & Epstein, J. Grading of prostatic adenocarcinoma: current state and 
prognostic implications. ​Diagn. Pathol.​ ​11,​​ 25 (2016). 
40. Aeffner, F. ​et al.​ The Gold Standard Paradox in Digital Image Analysis: Manual Versus 
33 
 
 
 
 
 
 
Automated Scoring as Ground Truth. ​Arch. Pathol. Lab. Med.​ ​141,​​ 1267–1275 (2017). 
41. Wang, D., Khosla, A., Gargeya, R., Irshad, H. & Beck, A. H. Deep Learning for Identifying 
Metastatic Breast Cancer. ​arXiv [q-bio.QM]​ (2016). 
42. Ehteshami Bejnordi, B. ​et al.​ Deep learning-based assessment of tumor-associated stroma 
for diagnosing breast cancer in histopathology images. in ​2017 IEEE 14th International 
Symposium on Biomedical Imaging (ISBI 2017)​ (2017). doi:​10.1109/isbi.2017.7950668 
43. Weinstein, J. N. ​et al.​ The Cancer Genome Atlas Pan-Cancer analysis project. ​Nat. Genet. 
45,​​ 1113–1120 (2013). 
44. Liu, J. ​et al.​ An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality 
Survival Outcome Analytics. ​Cell​ ​173,​​ 400–416.e11 (2018). 
45. Stephenson, A. J. ​et al.​ Defining biochemical recurrence of prostate cancer after radical 
prostatectomy: a proposal for a standardized definition. ​J. Clin. Oncol.​ ​24,​​ 3973–3978 
(2006). 
46. Szegedy, C., Vanhoucke, V., Ioffe, S., Shlens, J. & Wojna, Z. Rethinking the Inception 
Architecture for Computer Vision. in ​2016 IEEE Conference on Computer Vision and 
Pattern Recognition (CVPR)​ (2016). doi:​10.1109/cvpr.2016.308 
47. Epstein, J. I. ​et al.​ A Contemporary Prostate Cancer Grading System: A Validated 
Alternative to the Gleason Score. ​Eur. Urol.​ ​69,​​ 428–435 (2016). 
48. Cohen, J. A Coefficient of Agreement for Nominal Scales. ​Educ. Psychol. Meas.​ ​20,​​ 37–46 
(1960). 
 
34 
 
 
 
 
Supplementary Information 
 
Supplementary Table 1: Characteristics of the training and tuning datasets. 2 
Supplementary Table 2: Description of handling of variants. 3 
Supplementary Table 3: Analysis on slides excluded from validation set. 4 
Supplementary Table 4: Comparison of DLS to pathologists’ unadjusted accuracy. 6 
Supplementary Table 5: Comparisons of unadjusted accuracy on the validation set for the 
19 pathologists who each reviewed a subset of the validation dataset. 7 
Supplementary Table 6: Comparison of DLS to pathologists using other evaluation metrics. 8 
Supplementary Table 7: Comparison of %GP 3,4,5 quantitation. 9 
Supplementary Table 8: Comparison of %GP4 quantitation in GG2-3 slides and %GP5 
quantitation in GG4-5 slides. 10 
Supplementary Table 9: Sensitivity analysis excluding consult cases. 11 
Supplementary Table 10: Adverse Clinical Event Models Derived From Gleason Pattern 
Quantitation and Fine-Grained Gleason Pattern Quantitation. 12 
Supplementary Fig. 1: Confusion Matrices for the DLS and two pathologist subgroups 13 
Supplementary Fig. 2: Model and pathologist concordance with mixed grade labels. 14 
Supplementary Fig. 3: Extended visualization of Gleason patterns. 15 
Supplementary Fig. 4: Screenshot of the tool used for region-level annotations. 16 
Supplementary Fig. 5: Development of datasets used for training, tuning, and validation. 17 
Supplementary Methods 18 
Grading 18 
Pathologist Slide-Level Gleason Scoring Protocol 18 
Pathologist Region-Level Annotation Protocol 18 
Development of the Deep Learning System 19 
Hard-Negative Mining 21 
Fine-grained Gleason Pattern (GP) 22 
Statistical Analysis 22 
Comparison with the Cohort-of-29 22 
Bootstrap Approach for Confidence Intervals 23 
Supplementary Results 23 
DLS Region-level Errors 23 
Supplementary References 25 
 
  
1 
 Supplementary Table 1: Characteristics of the training and tuning datasets. 
 TCGA 
Tertiary 
Teaching 
Hospital 
Medical 
Laboratory Total (%) 
Number of patients  178 204 7 389 
Number of patients excluded due to 
non-gradable prostate cancer variants, 
extensive artifacts, or poor staining 
43 4 0 47 
Number of patients included in the 
study 135 200 7 342 
Number of slides 170 1,016 40 1,226 
With 
slide-level 
Gleason scores 
Number of slides 144 988 27 1,159 (100%) 
GG 1 (slides) 18 558 0 576 (50%) 
GG 2 (slides) 32 218 0 250 (22%) 
GG 3 (slides) 21 84 0 105 (9%) 
GG 4-5 (slides) 73 128 27 228 (20%) 
    GG 4 12 25  3 40 (3%) 
    GG 5 61 103  24 188 (16%) 
With 
region-level 
Gleason pattern 
annotations 
Number of slides 148 751 13 912 
Number of patches 14,422,449 97,737,450 455,947 112,615,846 (100%) 
Benign (patches) 11,188,435 93,691,585 364,838 105,244,858 (93%) 
GP3 (patches) 1,335,165 2,131,666 777 3,467,608 (3%) 
GP4 (patches) 1,898,849 1,210,348 67,346 3,176,543 (3%) 
GP5 (patches) 714,666 703,851 22,986 1,441,503 (1%) 
Supplementary Table 1: Characteristics of the train and tuning datasets. ​​In these datasets, 1-7 
slides from each patient were used, and each slide was reviewed by 3-5 pathologists. Slides were 
excluded from training/tuning if any pathologist deemed the slide ungradable due to variants or poor 
image quality. Slide-level Gleason scores and region-level Gleason pattern annotations were collected for 
overlapping subsets of these slides, with the breakdown described in the table above. 
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 Supplementary Table 2: Description of handling of variants. 
Prostate Cancer Variant Action 
Small Cell Carcinoma Excluded 
Mucinous prostatic adenocarcinoma Excluded 
Adenocarcinoma with signet ring cell like features Graded via ISUP 2014 recommendations​1 
Prostate ductal adenocarcinoma Excluded 
Basal cell carcinoma Excluded 
Histological Variant of Acinar Prostatic 
Adenocarcinoma 
Action 
Mucinous fibroplasia Graded via ISUP 2014 recommendations​1 
Foamy gland carcinoma Graded via ISUP 2014 recommendations​1 
Paneth cell-like neuroendocrine differentiation. Excluded 
Treated prostatic adenocarcinoma Excluded 
Pseudohyperplastic prostatic adenocarcinoma Graded via ISUP 2014 recommendations​1 
Intraductal carcinoma of the prostate When found in conjunction with Gleason Gradable 
tumor, only the Gleason gradable component is 
graded (consistent with ISUP 2014 
recommendations)​1 
Supplementary Table 2: Description of handling of prostate cancer variants and acinar 
adenocarcinoma histological variants. ​​Slides containing cancer variants and histological variants that 
are not Gleason gradable were excluded from the study (with the exception of intraductal carcinoma). 
Other variants are graded in a manner consistent with ISUP 2014 recommendations.  
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 Supplementary Table 3: Analysis on slides excluded from validation set. 
Slide Rationale for lack of confidence in diagnosis Specialist 1 GG 
Speciali
st 2 GG 
Speciali
st 3 GG 
DLS 
GG 
1 need IHC - high grade tumor, but needs IHC to assess/quantify IDC vs 
pattern 5 4-5 4-5 4-5 4-5 
2 need IHC - 4+3 vs 4+5 (pattern 5 based on cribriform necrosis), but chatter 
artifact makes it difficult to tell; also would do IHC to r/o IDC vs pattern 4/5 
areas 
3 3 3 4-5 
3 need IHC - high grade tumor case, but with areas of IDC vs pattern 4 vs 
pattern 4 with necrosis (pattern 5) 3 4-5 3 4-5 
4 need IHC - areas of IDC vs pattern 4 vs pattern 4 with necrosis (pattern 5) 2 3 2 2 
5 need IHC - likely 4+3 case, but given prominent areas of possible 
HGPIN/IDC need IHC to accurately quant pattern 4 3 3 3 3 
6 need IHC - given large areas of large cribriform glands (DDx HGPIN/IDC vs 
pattern 4), need IHC to accurately quantitate and grade 4-5 4-5 4-5 4-5 
7 need IHC - large areas of possible IDC; need IHC to r/o vs pattern 4 and for 
accurate pattern 4/tumor vol % 3 3 3 3 
8 need IHC - focal area of large cribriform glands present, would do both 
stains (r/o IDC vs pattern 4) and also levels as there may be necrosis (IDC 
vs pattern 5) 
2 2 2 2 
9 need IHC - definite invasive cancer present, but adjacent large cribriform 
glands with DDx of pattern 4 vs HGPIN needs IHCs to assess/quantitate 3 3 3 3 
10 need IHC - areas of large cribriform glands needing IHC to eval IDC vs 
pattern 4 3 3 3 3 
11 need IHC - areas of definite large crib irregular glands of pattern 4, but some 
areas of probable IDC also (need IHC to accurately quantitate) 4-5 4-5 4-5 4-5 
12 Needs another expert review. There is a pattern 3 that is not recognized. I 
don’t see a pattern 5. 3 3 3 4-5 
13 I suggest this case go to another expert as this case has many patterns and 
is good to our criteria titrated 3 4-5 3 4-5 
14 No agreement among initial reviewers - suggest another expert opinion 4-5 3 3 2 
15 Show to colleague(s) and order serial sections to confirm small % GG4 2 2 2 2 
16 Challenging slide - perhaps tissue was not well fixed as morphology was not 
great for grading. As such, I am not sure about GG5 - would show to a 
colleague(s). 
4-5 3 3 4-5 
17 Show to colleague(s) and order serial sections to confirm small % GG4 2 2 2 1 
18 Challenging case - would order serial sections to confirm minor GG5 (rule 
out tangential sectioning of GG4 poorly formed acini) as well as show to a 
colleague 
4-5 4-5 3 4-5 
19 require IHC 3 3 2 3 
20 Would use basal cell IHC to rule in/rule out intraductal carcinoma 3 3 2 4-5 
4 
 
Supplementary Table 3: Analysis on slides excluded from validation set due to genitourinary 
specialist lack of confidence when diagnosing.​​ 20 slides were excluded from the analysis in the main 
text where the specialist adjudicator was not able to provide a confident diagnosis. Consults were 
subsequently provided by the other two GU experts. Of the 12 cases where the original adjudicator and 
two consulting experts came to a consensus, the DLS was concordant on 9 (highlighted in green) and 
within 1 grouping on the remaining 3 (highlighted in red).  
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 Supplementary Table 4: Comparison of DLS to pathologists’ unadjusted 
accuracy. 
Grader Unadjusted accuracy for 
grade group (95% CI) 
p-value for 
comparison with DLS 
Deep learning system 0.698 (0.650, 0.746) n/a 
Mean among all 29 pathologists 0.610 (0.563, 0.660) 0.002 
Mean among 19-pathologist subgroup 0.596 (0.529, 0.659) <0.001 
Mean among 10-pathologist subgroup 
(A-J below)  
0.637 (0.588, 0.686) 0.006 
Pathologist A 0.526 (0.468, 0.577) <0.001 
Pathologist B 0.559 (0.502, 0.613) <0.001 
Pathologist C 0.592 (0.538, 0.644) <0.001 
Pathologist D 0.628 (0.574, 0.680) 0.027 
Pathologist E 0.647 (0.592, 0.695) 0.16 
Pathologist F 0.640 (0.589, 0.689) 0.083 
Pathologist G 0.668 (0.616, 0.716) 0.40 
Pathologist H 0.671 (0.616, 0.722) 0.45 
Pathologist I 0.716 (0.668, 0.764) 0.59 
Pathologist J 0.728 (0.683, 0.776) 0.33 
Supplementary Table 4: Comparison of unadjusted concordance between the deep learning 
system, the cohort of 29 pathologists, and 10 individual pathologists (A-J).​​ The cohort of 29 
pathologist comprised of 10 pathologists (A-J) that reviewed all 331 slides in the validation dataset and 19 
pathologist that each reviewed a subset of the validation dataset.  For the concordance of the individual 
19 pathologists see Supplementary Table 5.​ ​​Confidence intervals (CIs) were calculated with 1000 
bootstrap replications. The statistical significance of the comparisons were performed using the 
permutation test.  
6 
 Supplementary Table 5: Comparisons of unadjusted accuracy on the validation 
set for the 19 pathologists who each reviewed a subset of the validation dataset. 
Grader 
Number of slides in 
subset 
Pathologist accuracy 
on subset 
(95% CI) 
DLS accuracy on 
subset 
(95% CI) 
Pathologist ​K 62 0.306 (0.194, 0.435) 0.742 (0.629, 0.840) 
Pathologist ​L 64 0.422 (0.312, 0.555) 0.672 (0.570, 0.774) 
Pathologist ​M 55 0.545 (0.400, 0.655) 0.618 (0.500, 0.746) 
Pathologist ​N 58 0.552 (0.414, 0.655) 0.603 (0.483, 0.716) 
Pathologist ​O 54 0.556 (0.444, 0.648) 0.630 (0.519, 0.759) 
Pathologist ​P 57 0.561 (0.439, 0.684) 0.789 (0.675, 0.877) 
Pathologist ​Q 49 0.571 (0.438, 0.694) 0.694 (0.592, 0.807) 
Pathologist ​R 40 0.575 (0.450, 0.725) 0.700 (0.575, 0.850) 
Pathologist ​S 50 0.580 (0.440, 0.730) 0.700 (0.600, 0.800) 
Pathologist ​T 50 0.580 (0.460, 0.690) 0.700 (0.599, 0.850) 
Pathologist ​U 53 0.623 (0.500, 0.736) 0.642 (0.528, 0.774) 
Pathologist ​V 49 0.633 (0.510, 0.755) 0.673 (0.550, 0.786) 
Pathologist ​W 57 0.649 (0.509, 0.772) 0.737 (0.622, 0.851) 
Pathologist ​X 60 0.650 (0.500, 0.750) 0.700 (0.600, 0.800) 
Pathologist ​Y 46 0.674 (0.543, 0.783) 0.652 (0.510, 0.761) 
Pathologist ​Z 44 0.682 (0.500, 0.818) 0.705 (0.579, 0.818) 
Pathologist ​AA 50 0.700 (0.560, 0.820) 0.700 (0.540, 0.830) 
Pathologist ​AB 41 0.732 (0.610, 0.854) 0.732 (0.597, 0.878) 
Pathologist ​AC 53 0.736 (0.623, 0.887) 0.698 (0.584, 0.821) 
Supplementary Table 5​​: ​Comparisons of unadjusted accuracy on overlapping subsets of the 
validation set for the cohort of 19 pathologists.​​ Each pathologist reviewed a subset of the validation 
dataset, that collectively provided 3 annotations per slide for each of the 331 validation slides. In this 
subgroup analysis, the DLS’s accuracy is greater than that of 14 of the 19 pathologists. 
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 Supplementary Table 6: Comparison of DLS to pathologists using other 
evaluation metrics. 
Grader 
Population-adju
sted accuracy 
for grade group 
(95% CI) 
p-value for 
comparison 
with DLS 
Cohen’s 
kappa for 
grade group 
 (95% CI) 
p-value for 
comparison 
with DLS 
Accuracy for 
Gleason 
score (6-10) 
 (95% CI) 
p-value for 
comparison 
with DLS 
Deep learning 
system 
0.720 
(0.675, 0.762) n/a 
0.585 
(0.520, 0.651) n/a 
0.770 
(0.722, 0.813) n/a 
Mean among 
all 29 
pathologists 
0.628 
(0.578, 0.674) <0.001 
0.466 
(0.398, 0.527) 0.001 
0.681 
(0.638, 0.725) <0.001 
Pathologist A 0.515 (0.459, 0.569) <0.001 
0.365 
(0.290, 0.430) <0.001 
0.672 
(0.623, 0.723) 0.002 
Pathologist B 0.572 (0.519, 0.625) <0.001 
0.412 
(0.341, 0.481) <0.001 
0.593 
(0.540, 0.646) <0.001 
Pathologist C 0.615 (0.565, 0.660) <0.001 
0.457 
(0.389, 0.522) 0.001 
0.703 
(0.651, 0.752) 0.039 
Pathologist D 0.679 (0.635, 0.720) 0.16 
0.489 
(0.415, 0.556) 0.018 
0.659 
(0.607, 0.710) <0.001 
Pathologist E 0.603 (0.549, 0.655) 0.003 
0.506 
(0.428, 0.573) 0.10 
0.734 
(0.689, 0.777) 0.27 
Pathologist F 0.634 (0.581, 0.685) 0.011 
0.514 
(0.441, 0.577) 0.088 
0.729 
(0.683, 0.777) 0.19 
Pathologist G 0.656 (0.605, 0.712) 0.070 
0.530 
(0.459, 0.600) 0.21 
0.734 
(0.686, 0.782) 0.25 
Pathologist H 0.669 (0.618, 0.721) 0.12 
0.548 
(0.475, 0.618) 0.37 
0.690 
(0.638, 0.736) 0.007 
Pathologist I 0.727 (0.679, 0.775) 0.81 
0.613 
(0.548, 0.678) 0.45 
0.769 
(0.720, 0.815) >.99 
Pathologist J 0.758 (0.714, 0.801) 0.18 
0.622 
(0.561, 0.690) 0.33 
0.773 
(0.727, 0.818) >.99 
Supplementary Table 6: Comparison of other evaluation metrics (adjusted accuracy for grade 
group, Cohen’s Kappa for grade group, and accuracy for Gleason score) between the deep 
learning system (DLS), the cohort of 29 pathologists, and 10 individual pathologists (A-J).​​ The 
adjusted accuracy reflects a population-level GG distribution of 7397:8353:3106:1968.​2​ ​​Confidence 
intervals (CIs) were calculated with 1000 bootstrap replications. The statistical significance of the 
comparisons were performed using the permutation test.  
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 Supplementary Table 7: Comparison of %GP 3,4,5 quantitation. 
Grader 
Mean absolute 
error for %GP3 
(95% CI) 
p-value for 
comparison 
with DLS 
Mean absolute 
error for %GP4 
(95% CI) 
p-value for 
comparison 
with DLS 
Mean absolute 
error for %GP5 
(95% CI) 
p-value for 
comparison 
with DLS 
Deep learning 
system 
11.9 
(10.0, 13.9) n/a 
11.8 
(10.5, 13.2) n/a 
4.5 
(3.4, 5.7) n/a 
Mean among 
all 29 
pathologists 
16.0 
(13.3, 18.7) 0.004 
17.8 
(15.1, 20.7) <0.001 
5.2 
(3.9, 6.6) 0.26 
Pathologist A 19.4 (16.9, 21.8) <0.001 
22.0 
(19.3, 24.7) <0.001 
4.2 
(3.0, 5.4) 0.43 
Pathologist B 19.5 (17.0, 22.3) <0.001 
22.6 
(19.8, 25.5) <0.001 
5.4 
(3.9, 6.9) 0.19 
Pathologist C 18.5 (15.9, 21.1) <0.001 
21.0 
(18.3, 23.9) <0.001 
4.2 
(3.1, 5.6) 0.49 
Pathologist D 13.1 (11.3, 14.9) 0.36 
15.8 
(13.9, 17.7) <0.001 
5.0 
(3.7, 6.5) 0.50 
Pathologist E 15.6 (13.7, 17.6) 0.002 
18.8 
(16.8, 20.7) <0.001 
4.3 
(3.3, 5.6) 0.80 
Pathologist F 15.2 (13.0, 17.4) 0.002 
17.0 
(14.7, 19.3) <0.001 
4.9 
(3.6, 6.2) 0.51 
Pathologist G 10.4 (9.1, 12.0) 0.19 
14.6 
(12.8, 16.5) 0.001 
6.9 
(5.5, 8.4) <0.001 
Pathologist H 10.2 (8.8, 11.7) 0.12 
14.5 
(12.5, 16.3) 0.003 
6.5 
(4.9, 8.2) <0.001 
Pathologist I 9.8 (8.3, 11.2) 0.083 
11.9 
(10.3, 13.4) >0.99 
4.2 
(3.2, 5.5) 0.55 
Pathologist J 10.2 
(8.6, 11.8) 0.13 
12.2 
(10.5, 14.0) 0.68 
3.9 
(2.9, 5.0) 0.10 
Supplementary Table 7: Comparison of Gleason pattern (GP) quantitation between the deep 
learning system (DLS), the cohort of 29 pathologists, and 10 individual pathologists. ​​Confidence 
intervals (CIs) were calculated with 1000 bootstrap replications. The statistical significance of the 
comparisons were performed using the permutation test. 
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 Supplementary Table 8: Comparison of %GP4 quantitation in GG2-3 slides and 
%GP5 quantitation in GG4-5 slides. 
Grader Mean absolute 
error for %GP4 
in GG 2-3 slides 
(95% CI) 
p-value for 
comparison with 
DLS 
Mean absolute 
error for %GP5 
in GG 4-5 slides 
(95% CI) 
p-value for 
comparison with 
DLS 
Deep Learning 
System 
13.0 (11.5, 14.7) n/a 18.7 (14.3, 23.2) n/a 
Mean among all 
29 pathologists 
20.5 (17.6, 24.0) <0.001 22.0 (18.0, 26.9) 0.30 
Pathologist A 27.3 (23.8, 30.8) <0.001 18.0 (13.5, 23.2) 0.76 
Pathologist B 25.1 (21.7, 28.7) <0.001 24.7 (19.3, 30.4) 0.076 
Pathologist C 25.5 (22.1, 28.9) <0.001 19.6 (14.0, 25.4) 0.79 
Pathologist D 19.1 (16.6, 21.7) <0.001 24.2 (19.0, 29.6) 0.12 
Pathologist E 19.3 (17.0, 21.7) <0.001 20.6 (16.1, 25.0) 0.58 
Pathologist F 18.0 (15.5, 20.6) <0.001 19.0 (13.9, 24.3) 0.89 
Pathologist G 16.1 (14.0, 18.3) 0.007 20.9 (15.7, 26.3) 0.35 
Pathologist H 15.4 (13.2, 17.6) 0.044 24.0 (18.2, 31.0) 0.046 
Pathologist I 13.9 (12.0, 15.8) 0.38 17.5 (12.8, 22.7) 0.49 
Pathologist J 14.6 (12.6, 16.8) 0.12 17.4 (13.1, 22.0) 0.53 
Supplementary Table 8: Comparison of Gleason pattern (GP) in Grade Groups (GG) 2-3 and 4-5 
between the deep learning system (DLS), the cohort of 29 pathologists, and 10 individual 
pathologists (A-J). ​​Confidence intervals (CIs) were calculated with 1000 bootstrap replications. The 
statistical significance of the comparisons were performed using the permutation test.   
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 Supplementary Table 9: Sensitivity analysis excluding consult cases.  
Grader 
Number of Slides 
excluded due to 
indication of a 
non-confident 
diagnosis 
Pathologist’s 
accuracy 
excluding consult 
cases (95% CI) 
DLS accuracy 
excluding the 
same cases 
 (95% CI) 
p-value for 
comparison with 
DLS 
Pathologist A 3 52.0 (46.7, 57.3) 69.2 (64.2, 74.1) <0.001 
Pathologist B 6 56.2 (50.6, 61.8) 69.6 (64.8, 74.7) <0.001 
Pathologist C 2 59.9 (54.2, 65.3) 69.4 (64.7, 74.3) 0.002 
Pathologist D 10 63.3 (58.0, 68.5) 69.8 (65.0, 74.4) 0.048 
Pathologist E 3 64.7 (59.7, 69.7) 69.3 (64.5, 74.4) 0.22 
Pathologist F 7 63.7 (58.4, 68.6) 69.5 (64.7, 74.5) 0.074 
Pathologist G 2 67.0 (62.0, 72.2) 69.5 (64.7, 74.4) 0.50 
Pathologist H 8 66.5 (61.5, 71.8) 69.6 (64.8, 74.4) 0.37 
Pathologist I 9 71.4 (66.9, 76.0) 69.6 (64.5, 74.4) 0.60 
Pathologist J 1 73.8 (69.1, 78.6) 69.5 (64.6, 74.6) 0.17 
Supplementary Table 9: Comparison between pathologists and DLS on Gleason scoring excluding 
slides indicated by pathologists as non-confident diagnosis. ​​The results are qualitatively similar to 
the results in Supplementary Table 4 with no material differences. Confidence intervals (CIs) were 
calculated with 1000 bootstrap replications. The statistical significance of the comparisons were 
performed using the permutation test. 
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 Supplementary Table 10: Adverse Clinical Event Models Derived From Gleason 
Pattern Quantitation and Fine-Grained Gleason Pattern Quantitation.  
 
Source of Gleason pattern 
quantitation 
Input features to Cox 
regression model describing 
tumor composition: (all based 
on % Gleason pattern) 
C-index (95% CI) 
Cohort-of-29 general 
pathologists 
3, 4, 5 0.674 (0.564, 0.782) 
Genitourinary specialist 
pathologists 
3, 4, 5 0.690 (0.582, 0.800) 
DLS 3, 4, 5 0.697 (0.579, 0.790) 
DLS 3, 3.5, 4, 5 0.704 (0.586, 0.814) 
DLS 3, 3.5, 4, 4.5, 5 0.702 (0.577,0.812) 
Supplementary Table 10: Comparison of Cox models for adverse clinical events 
(progression/biochemical recurrence) trained directly on quantified Gleason patterns and 
fine-grained Gleason Patterns.​​ Cox proportional hazards regression models were trained and evaluated 
on the validation set (n=331 slides), with Gleason patterns quantitation as input features. Features were 
provided by the cohort-of-29 pathologists, genitourinary specialists comprising the reference standard, 
and the DLS. As proof-of-concept, Cox models were also trained with additional features that provide 
finer-grained representations of tumor differentiation (see “Fine-grained Gleason Pattern” in 
Supplementary Methods). Confidence intervals (CI) were calculated via bootstrapping, and the median 
concordance index is presented for the cohort-of-29 pathologists (see Supplementary Methods).   
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 Supplementary Fig. 1: Confusion Matrices for the DLS and two pathologist 
subgroups  
 
 
Supplementary Fig. 1: Confusion matrices highlighting the distribution of errors made by the DLS 
and two pathologist subcohorts. ​​The DLS is compared to the subgroup of 10 pathologists where each 
pathologist individually annotated every validation set slide, as well as the subgroup of 19 pathologists 
that collectively provided 3 reviews for every slide. The DLS shows greater accuracy in classifying slides 
as GG1, GG2, and GG4-5, and lower accuracy in classification of GG3 on the validation set as compared 
to these cohorts.   
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Supplementary Fig. 2: Model and pathologist concordance with mixed grade 
labels. 
 
Supplementary Fig. 2: Model and pathologist concordance with mixed grade labels. ​​When 
pathologists could not assign a single Gleason pattern to a region, they were instructed to assign a mixed 
grade label. Available mixed grade labels were ‘3+4’, ‘4+3’, ‘4+5’, and ‘5+4’. These indicate that a region 
exhibits histological patterns characteristic of both Gleason patterns at the level of glands, and they are 
an extension to the Gleason grading system which allow humans to represent a small slice of the 
continuum of Gleason grading. To further investigate the deep learning system’s ability to quantitatively 
represent the ambiguities present in the Gleason grading system, we examine the model’s output in those 
cases in which a pathologist provided a mixed grade. ​A, ​​Distributions of predicted likelihood of each GP 
by the DLS on patches labeled as a mixed grade by at least one pathologist. The DLS represents 
“in-between” patterns by exhibiting mixed likelihood between multiple labels. ​B, ​​The distribution of other 
pathologist grades for those patches which were given a mixed grade by at least one pathologist.   
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 Supplementary Fig. 3: Extended visualization of Gleason patterns.  
Supplementary Fig. 3: Extended visualization of Gleason patterns.​​ The continuum of prostate cancer 
Gleason Patterns (GP) learned by the DLS reveals finer categorization of the well-to-poorly differentiated 
spectrum. The top row highlights the DLS GP categorization followed by H&E images that are predicted 
to be the corresponding quantitative GP. Columns 1, 5, and 9 represent 100% confidence in GP 3, 4, and 
5 respectively.  The columns in between represent quantitative GPs that are in between these defined 
categories.  
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Supplementary Fig. 4: Screenshot of the tool used for region-level annotations. 
 
Supplementary Fig. 4: Screenshots of the tool used for region-level annotations.​​ ​A, ​​An overview of 
the tool zoomed out to 0.625X. A user annotates a region by first selecting a label category on the left and 
then outlining the corresponding regions direct on the slide. This custom free-hand drawing tool also has 
the ability to zoom between different objective powers as appropriate. ​B, ​​Screenshots of annotations on 
tissue regions at additional magnifications: 2.5X and 10X. Most annotations were done between 5-20X.  
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 Supplementary Fig. 5: Development of datasets used for training, tuning, and validation.  
Region-level datasets and the slide-level training datasets were provided by pathologists, while the 
generation of the slide-level tuning and validation datasets involved genitourinary expert pathologists. 
More details can be found in the Grading sections of the Methods and the Supplementary Methods.   
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Supplementary Methods 
Grading 
Pathologist Slide-Level Gleason Scoring Protocol 
Slides used for training were reviewed by at least 3 and up to 7 pathologists (median 4). The label 
for each slide was determined by the most common annotation provided by the pathologists, while 
breaking ties in favor of the more severe grade to encourage higher DLS sensitivity. Tuning slides were 
initially reviewed by 3 to 5 pathologists and subsequently adjudicated by 1 of 3 genitourinary specialists 
(similar to the validation dataset). 
We derived the slide-level Gleason score (e.g. 3+4) from the predominant GP and next-most-common 
GP. This is used instead of the directly provided Gleason scores because we noted inconsistent 
application of tertiary replacement (replacing the secondary Gleason score with ‘5’ if %GP5 is greater 
than 5%), leading to even greater diagnostic variability.​2​ The GG (e.g. GG2) was then directly determined 
using the Gleason score using the published definitions.​2​ Pathologists were additionally instructed to note 
if a slide contained histologic variants (listed in Supplementary Table 2), did not contain tumor, or if they 
were not confident in their diagnosis. 
Pathologist Region-Level Annotation Protocol 
The region-annotations for all datasets (training, tuning, and validation) were performed using 
custom free-hand drawing tools in a custom histopathology viewer (see Supplementary Fig. 4) with the 
ability to zoom between magnifications. Most annotations were performed between 5X and 20X 
magnifications. Artifacts that affected the ability to make a confident interpretation were labeled as 
artifacts, and regions where the pathologists were not able to assign confident categorizations based on 
their best clinical judgement were assigned a “consult” label. Regions where different GPs were either 
ambiguous or difficult to delineate exactly were assigned mixed-grade labels such as  ‘3+4’. Perineural 
and lymphovascular invasive tumor and intraductal carcinoma were labeled as non-Gleason-gradable 
tumors. 
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For the training slides, at least one pathologist non-exhaustively annotated characteristic regions 
of each slide (annotated tissue for each slide <1% to 100%, median of 57%). For the tuning slides, we 
obtained higher-confidence labels by asking three pathologists for exhaustive annotations. In this set, to 
improve annotation efficiency (retaining slide-level diversity while reducing the overall annotation 
workload), the pathologists annotated only a subset of each slide, specifically two 3.8x3.8mm square 
regions from each quadrant on the slide. The locations of the two squares within each quadrant were 
randomly selected, and all three pathologists annotated the same eight regions (annotated tissue for each 
slide <1% to 35%, median of 14%). Only image patches with concordance between at least two 
annotators were used. 
To train the stage-1 DLS, we processed the training dataset annotations to retain only regions 
with unambiguous labels. Ambiguity arising from multiple different labels were resolved by majority vote. 
Regions labeled ‘artifact’ were interpreted as non-tumor to reduce false positive predictions on 
artifact-containing regions. Regions labeled as ‘mixed-grade’ were interpreted as the primary pattern 
(​e.g.​, ‘5+4’ was interpreted as GP5), based on empirical observations of a resultant boost in stage-1 
region-level accuracy. For the tuning datasets, only regions for which all three annotators provided a label 
were considered (similar to the validation dataset). In the main text, we report results only for patches 
labeled non-tumor, GP3, GP4, GP5. The analysis of image patches that are labeled with mixed-grades 
are presented in Supplementary Fig. 2. 
Development of the Deep Learning System  
We used a Inception-V3​3​ image classification network, with fewer filters per layer 
(depth_multiplier=0.1) and modified to be fully-convolutional to improve inference throughput on 
whole-slide images (manuscript under review). To avoid introducing grid artifacts, the fully-convolutional 
modification involved using ‘VALID’ instead of ‘SAME’ padding in convolutions and differential cropping of 
the output of ‘branches’ in the Inception architecture. This network takes as input image patches of size 
911x911 pixels at 10X magnification (equivalent to 911 ​✕ ​911 µm). The region “assessed” by the network 
is a 32 ​✕ ​32 µm region centered in each image patch. 
The training process involved feeding image patches into the network with a specific sampling 
strategy to avoid bias towards specific slides or classes: first select a class according to the ratios 4:2:2:1 
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for the four classes respectively, then select a slide containing regions labeled as that class, and finally 
select an image patch from that slide. To help improve generalization performance, we applied data 
augmentation techniques to randomly perturb the actual images seen by the neural network (image 
perturbations for saturation, contrast, brightness, hue, and orientation) during training.​4​ Training was 
performed in TensorFlow​5​ using an RMSProp optimizer​6​ and the softmax cross-entropy loss function. 
Hyperparameters such as the four-class sampling ratios, magnitude of image perturbations, the learning 
rate decay schedule, and L2 regularization decay were tuned via Gaussian-Bandit search on ​Google 
Vizier​.​7​  After tuning model hyperparameters, hard negative mining and ensembling were employed to 
further improve model performance. See below section for details of hard-negative mining. 
After model convergence (as determined by the patch-level four-way classification performance 
on the tuning set, as measured by Cohen’s kappa), we applied ensembling at three levels. First, the 
actual network weights used were smoothed using an exponential moving average with decay constant of 
0.9999. Second, for each patch, the model predictions across eight image orientations (4 90° rotations 
and 2 left-right flips) were averaged using the geometric mean. Lastly, these orientation-averaged 
predictions were again averaged across four independently trained models (each with a separate 
hard-negative mining process), again using the geometric mean. 
In the second stage of the DLS, we first calibrated each region’s class predicted likelihoods. The 
calibration weights were determined empirically to produce the best slide-level predictions on the tuning 
set. Next, to obtain a categorical prediction for each patch, we applied the argmax function. Finally, each 
slide’s patch-level predictions were summarized as four features: %Tumor, %GP3, %GP4, and %GP5. 
We linearly rescaled these features to have a minimum of 0 and a maximum of 1 in the training set, and 
trained a k-nearest neighbor (kNN) model for each prediction task: 4-way GG classification (GG 1, 2, 3 or 
4-5), and each of the three binary classifications of GG ​>​ 2, GG ​>​ 3, and GG ​>​ 4. The hyperparameter “k” 
(number of nearest neighbors) and neighbor-weighting method (uniform versus reciprocal of distance) 
were selected based on the performance of each model on the tuning set, as measured by kappa for GG 
and area under receiver operating characteristic (AUC) for the binary predictions. Our final selected 
hyperparameters were k=24 with uniform neighbor weighting. In addition, we evaluated the performance 
of several other machine learning algorithms, such as logistic regression, and random forest on the tuning 
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set. kNN was selected to avoid over-fitting based on the limited size of the slide-level dataset and for ease 
of interpretability (as visualized in Fig. 1). 
Hard-Negative Mining 
Our DLS stage-1 development process includes large scale, continuous “hard-negative mining” 
which aims to improve algorithm performance by running inference on the entire training dataset to isolate 
the hardest examples and further refine the algorithm using these examples.  
In hard negative mining, inference was run hourly by applying the partially-trained network to the 
entire training dataset (over 112 million image patches) for the entire duration of the training. These 
inference results were then used to alter the patch-sampling probabilities for every slide in the training set. 
For a given class in each slide, these sampling probabilities were initialized at the start of training to be 
uniform across all image patches. After every inference round, the sampling probabilities were updated to 
be proportional to the cross-entropy loss of each patch, such that incorrect classifications were sampled 
more frequently. In other words, as training proceeded, the DLS learned from harder and harder 
examples, which improved its accuracy more efficiently than random examples. While previous works 
employing deep learning on histopathology images have employed hard negative mining in an offline 
“batch-mode”​8–10​, we observed that performance improves with the frequency of inference on the entire 
training dataset, resulting in the “quasi-online” hard-negative mining approach (>30,000 DLS stage-1 
inferences per second) used here. We anticipate that the benefits of this continuous hard negative mining 
approach may be applicable to developing other deep learning algorithms on histopathology images as 
well. 
For histopathology applications on whole-slide imaging, hard negative mining is a computationally 
expensive process, requiring inference over 112 million image patches in our training dataset. While 
previous works employing deep learning on histopathology images have employed hard negative mining 
in an offline “batch-mode”​8–10​, we observed that performance improves with the frequency of inference on 
the entire training dataset, resulting in the “quasi-online” hard-negative mining approach (>30,000 DLS 
stage-1 inferences per second) used here. We anticipate that the benefits of this continuous hard 
negative mining approach may be applicable to developing other deep learning algorithms on 
histopathology images as well. 
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 Fine-grained Gleason Pattern (GP) 
To provide a more quantitative GP that smoothly interpolates between existing GPs (3, 4, and 5), we 
processed the calibrated DLS-predicted likelihood for each GP. First, the predictions for the two GPs with 
highest confidences were used to interpolate between the two GPs using the formula likelihood​1​ / 
(likelihood​1​ + likelihood​2​). For example, if the GP 3,4,5 predictions were [0.7, 0.2, 0.1], then the computed 
value was 0.7 / (0.7 + 0.2) = 0.78, and the quantitative GP was 3+0.78 = 3.78. To visualize these 
quantitative GPs (e.g. in Fig. 4a), we used the International Commission on Illumination “Lab” (CIELAB) 
color space, which is designed to be perceptually uniform with respect to the underlying numerical values. 
To select regions that represent desired quantitative GPs (Fig. 4c and Supplementary Fig. 3), we located 
the image patches among all validation dataset slides for which the computed quantitative GP most 
closely matched the desired GP (e.g. 3.5). 
Statistical Analysis 
Comparison with the Cohort-of-29 
Comparison of the DLS with the cohort-of-29 pathologists required a modified permutation test​11 
to account for the different numbers of slide-level annotations provided by each pathologist. Specifically, 
10 pathologists annotated all the slides (331 annotations each), while 19 pathologists collectively 
annotated all the slides 3 times (about 50±10 annotated slides by each pathologist). The 10 pathologists 
that annotated all the slides were selected based on slide reviewing speed and availability. To represent 
each pathologist equally, we modify the permutation test as follows: define our test statistic as the 
difference between the DLS accuracy and the mean accuracy among pathologists in the cohort-of-29. In 
each iteration of the permutation test, for each slide, randomly swap the model's given rating with one of 
the 14 ratings given for that slide (allowing the model to "swap" with itself with probability 1/14), and 
compute the test statistic on the result. After 5000 iterations, this gives a null distribution of the test 
statistic against which we compare the observed difference to compute a two-tailed p value. 
In the risk stratification analyses, the cohort-of-29 pathologists annotations were sampled to 
approximate equal representation of each pathologist. For each slide, the sampled annotation can come 
22 
 
from either one of  subgroup-of-10 annotations or one of the 3 available subgroup-of-19 annotations. 
Specifically, for each slide, an annotation was selected from one of the 10 available subgroup-of-10 
annotations with 1/29 probability, or from one of the 3 available subgroup-of-19 annotations with 
(19/29)*(1/3) probability. 
Bootstrap Approach for Confidence Intervals 
To compute confidence intervals for the pools of 10, 19, and 29, we bootstrapped both slides and 
annotators by resampling both with replacement in each iteration of the bootstrap. In the case of the pool 
of 29, to replicate our experimental design in each iteration, we separately resampled the subsets of 10 
and 19. 
 
Supplementary Results 
DLS Region-level Errors 
Here, we present a qualitative analysis of the errors made by the DLS’s first stage, at the region 
level. Several errors were related to spatial localization. For example, the spatial extent of each predicted 
Gleason pattern region was sometimes imprecise; if two tumor-containing regions were separated by a 
small strip of non-tumor tissue, the DLS would sometimes categorize the intervening non-tumor as tumor.  
Similarly, delineating the precise stroma-tumor interface was difficult for the DLS, in particular for 
GP5 and stroma (non-tumor). This was likely because GP5 can present as individual tumor cells in a 
background of connective tissue, and outlining each individual cell was impractical. The “impurity” of the 
underlying region-level annotation made it difficult to develop a DLS that was precision with respect to the 
boundary. 
In many other cases, the errors made by the DLS was one where the underlying histology was 
ambiguous, such as when a tangential cut into a GP3 region caused it to resemble the fused-gland 
pattern that defines GP4. Because the DLS was trained to interpret the image patch surrounding the 
region, it will not take into account context from beyond its input image. 
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The remaining region-level errors involved true prediction mistakes that will naturally improve with 
more data. The second stage of the DLS is fairly robust against all of these errors by summarizing the 
predictions from all regions on the slide as a small number of features. 
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